204 related articles for article (PubMed ID: 8075648)
1. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
[TBL] [Abstract][Full Text] [Related]
2. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations.
Bardeesy N; Beckwith JB; Pelletier J
Cancer Res; 1995 Jan; 55(2):215-9. PubMed ID: 7812946
[TBL] [Abstract][Full Text] [Related]
3. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
5. Mutations of p53 in Wilms' tumors.
Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
7. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
8. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
9. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
10. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
Ramani P; Cowell JK
J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
[TBL] [Abstract][Full Text] [Related]
11. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
[TBL] [Abstract][Full Text] [Related]
12. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations and MDM-2 amplification in renal cell cancers.
Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
[TBL] [Abstract][Full Text] [Related]
14. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
15. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
16. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
[TBL] [Abstract][Full Text] [Related]
17. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors.
Ramachandran C; Melnick SJ; Escalon E; Jhabvala P; Khatib Z; Alamo A; Smith S
Anticancer Res; 2000; 20(5C):3759-65. PubMed ID: 11268451
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
Tretiakova M; Turkyilmaz M; Grushko T; Kocherginsky M; Rubin C; Teh B; Yang XJ
J Clin Pathol; 2006 Dec; 59(12):1272-7. PubMed ID: 16556665
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
20. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
